UBS Group Has Lowered Expectations for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price lowered by UBS Group from $35.00 to $27.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

XRAY has been the subject of several other research reports. Needham & Company LLC lowered their price objective on shares of DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Leerink Partners lowered shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Leerink Partnrs downgraded shares of DENTSPLY SIRONA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 7th. StockNews.com cut shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. Finally, Robert W. Baird dropped their target price on DENTSPLY SIRONA from $31.00 to $24.00 and set a “neutral” rating on the stock in a research report on Friday, November 8th. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $29.22.

DENTSPLY SIRONA Price Performance

XRAY opened at $19.39 on Tuesday. DENTSPLY SIRONA has a 52-week low of $17.21 and a 52-week high of $37.60. The company has a 50 day moving average of $22.29 and a two-hundred day moving average of $24.62. The company has a market cap of $3.85 billion, a P/E ratio of -9.37, a P/E/G ratio of 1.94 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.02. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The firm had revenue of $951.00 million during the quarter, compared to analysts’ expectations of $939.10 million. During the same period in the prior year, the company earned $0.49 EPS. The firm’s revenue was up .4% on a year-over-year basis. On average, analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently bought and sold shares of the company. First Eagle Investment Management LLC increased its stake in shares of DENTSPLY SIRONA by 33.6% in the second quarter. First Eagle Investment Management LLC now owns 13,069,900 shares of the medical instruments supplier’s stock valued at $325,571,000 after purchasing an additional 3,283,965 shares during the period. Dimensional Fund Advisors LP grew its holdings in DENTSPLY SIRONA by 42.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,420,445 shares of the medical instruments supplier’s stock worth $110,118,000 after buying an additional 1,308,411 shares in the last quarter. Cooke & Bieler LP increased its position in DENTSPLY SIRONA by 16.2% in the 2nd quarter. Cooke & Bieler LP now owns 7,506,845 shares of the medical instruments supplier’s stock valued at $186,996,000 after acquiring an additional 1,046,105 shares during the period. Invenomic Capital Management LP acquired a new position in DENTSPLY SIRONA during the 3rd quarter worth $23,724,000. Finally, National Bank of Canada FI grew its stake in shares of DENTSPLY SIRONA by 684.6% in the second quarter. National Bank of Canada FI now owns 876,400 shares of the medical instruments supplier’s stock worth $21,586,000 after purchasing an additional 764,700 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.